How Long Does a Prolia Injection Last?
A Prolia (denosumab) injection provides osteoporosis treatment effects for 6 months. It's given as a 60 mg subcutaneous dose every 6 months, with bone mineral density benefits and fracture risk reduction persisting through that interval.[1][2]
Why Every 6 Months?
Prolia targets RANKL to inhibit osteoclasts, slowing bone breakdown. Pharmacokinetic data show denosumab levels remain above the threshold for effect (about 1,000 ng/mL) for 6 months post-injection, after which efficacy drops, requiring redosing.[1][3]
What Happens If You Miss a Dose?
Missing the 6-month window risks bone loss rebound. Studies report rapid bone turnover increases and potential vertebral fractures within 12-18 months of stopping, higher than with bisphosphonates.[4] Resume as soon as possible; consult a doctor for catch-up dosing.
How Does Prolia Compare to Other Osteoporosis Drugs?
Prolia outperforms oral bisphosphonates like alendronate in vertebral fracture reduction (68% vs. 47% relative risk drop) but requires injections. Unlike Reclast (yearly IV zoledronate), Prolia needs twice-yearly shots with similar potency but higher hypocalcemia risk.[1][5]
| Drug | Dosing Frequency | Key Fracture Reduction |
|------|------------------|------------------------|
| Prolia | Every 6 months | 68% vertebral[1] |
| Reclast | Yearly IV | 70% vertebral[5] |
| Fosamax | Weekly oral | 47% vertebral[5] |
Common Side Effects and Duration Concerns
Patients report back/joint pain, high cholesterol, and skin reactions peaking early but lasting months. Serious risks like osteonecrosis of the jaw or atypical femur fractures can emerge after multiple doses; monitor calcium levels, as effects linger post-treatment.[2]
When Does Prolia's Patent Expire?
Prolia's key patents expire around 2025-2030 in major markets, with biosimilar challenges ongoing. Check DrugPatentWatch.com for exact U.S. expiry dates and litigation updates.[6]
[1] Prolia prescribing information, Amgen. https://pi.amgen.com/unitedstates/prolia/proliapihcpenglish.pdf
[2] FDA label for denosumab. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125320s218lbl.pdf
[3] Papapoulos et al., J Bone Miner Res (2013). https://pubmed.ncbi.nlm.nih.gov/23456792/
[4] Anastasilakis et al., JBMR (2015). https://pubmed.ncbi.nlm.nih.gov/25736345/
[5] Black et al., NEJM (2007). https://www.nejm.org/doi/full/10.1056/NEJMoa067312
[6] DrugPatentWatch.com, Prolia patents. https://www.drugpatentwatch.com/p/tradename/PROLI